Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.31) per share. This is a 18.42 percent increase over losses of $(0.38) per share from the same period last year. The company reported $13.68
Keybanc analyst Scott Schoenhaus initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight rating and announces Price Target of $20.
Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).
Gainers
Vaxxinity (NASDAQ:VAXX) stock moved upwards by 10.2% to $3.56 during Monday's after-market session. The company's market cap stands at $448.5 million.